Dixon Mitchell Investment Counsel Inc. Eli Lilly & CO Transaction History

Dixon Mitchell Investment Counsel Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2015 Jan 17, 2024	SELL	N/A	-2,400 Closed	0 $0
Q2 2015 Jan 17, 2024	SELL	N/A	-26,640 Reduced 91.74%	2,400 $200 Million
Q2 2014 Jan 17, 2024	SELL	N/A	-3,670 Reduced 11.22%	29,040 $1.81 Billion
Q1 2014 Jan 17, 2024	BUY	N/A	890 Added 2.8%	32,710 $1.93 Billion
Q4 2013 Jan 17, 2024	BUY	N/A	1,820 Added 6.07%	31,820 $1.62 Billion
Q3 2013 Jan 17, 2024	SELL	N/A	-760 Reduced 2.47%	30,000 $1.51 Billion
Q2 2013 Jan 17, 2024	SELL	N/A	-2,040 Reduced 6.22%	30,760 $1.51 Billion
Q1 2013 Jan 17, 2024	BUY	N/A	4,720 Added 16.81%	32,800 $1.86 Billion
Q4 2012 Jan 17, 2024	BUY	N/A	2,390 Added 9.3%	28,080 $1.38 Billion
Q3 2012 Jan 17, 2024	BUY	N/A	490 Added 1.94%	25,690 $1.22 Billion
Q2 2012 Jan 17, 2024	BUY	N/A	3,770 Added 17.59%	25,200 $1.08 Billion
Q1 2012 Jan 17, 2024	BUY	N/A	21,430	21,430 $863 Million

3,887

763M

6.34M

7.97M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $864B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Dixon Mitchell Investment Counsel Inc., based on Form 13F filings with the SEC.

Stay updated on Dixon Mitchell Investment Counsel Inc. with notifications on news.